Price
No data yet.
Social Signal Score
Revenue
$4.14B+6.56%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard D. Francis
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 32,008
- Beta
- 0.88
- Country
- IL
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 0.82
Financials
Revenue
$4.14B+6.6%Net Income
$-576.00M-297.3%EBITDA
$-19.00M-101.8%Free Cash Flow
$307.00M-19.8%EPS (diluted)
$-0.49-288.5%Shares Outstanding (diluted)
1.18B+6.5%Operating Expenses
$1.28BCash & Debt
$3.65BRevenue by Segment (annual)
$17.26BDividend per Share
$0.09Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $17.26B | $1.41B | $1.23 |
| 2024 | $16.54B | $-1.64B | $-1.45 |
| 2023 | $15.85B | $-559.00M | $-0.50 |
| 2022 | $14.93B | $-2.45B | $-2.20 |
| 2021 | $15.88B | $417.00M | $0.38 |
| 2020 | $16.66B | $-3.99B | $-3.64 |
| 2019 | $16.89B | $-999.00M | $-0.92 |
| 2018 | $18.85B | $-2.15B | $-2.11 |
| 2017 | $22.39B | $-16.27B | $-16.01 |
| 2016 | $21.90B | $329.00M | $0.07 |
| 2015 | $19.65B | $1.59B | $1.84 |
| 2014 | $20.27B | $3.06B | $3.58 |
| 2013 | $20.31B | $1.27B | $1.49 |
| 2012 | $20.32B | $1.96B | $2.25 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from TEVA's reported EPS growth of -4.5% a year over 13 years.
- EPS in 5 years
- $0.97
- Implied price
- $24.37
- Return from $37.70
- -8.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $12.12 — -67.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| -14.5% | -24.0% | -20.8% | -18.0% | -15.5% | -13.3% |
| -9.5% | -19.6% | -16.1% | -13.2% | -10.5% | -8.2% |
| -4.5% | -15.2% | -11.5% | -8.4% | -5.6% | -3.1% |
| 0.5% | -10.7% | -6.9% | -3.6% | -0.7% | 1.9% |
| 5.5% | -6.3% | -2.2% | 1.2% | 4.3% | 7.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Negative
…ARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ecopipam, with a targeted action (PDUFA) date late in the first quarter of 2027. Ecopipam is a first-in-class investigational therapy for the treatment of pediatric patients with Tourette syndrome. This milestone advan…
View source ↗
Earnings
Wed, Nov 4(in 3 months)
Consensus estimate $0.73 per share
Typical surprise +6.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$0.02 vs $0.08miss
- Wed, Apr 29$0.53 vs $0.50beat
- Wed, Jan 28$0.96 vs $0.65beat
- Wed, Nov 5$0.78 vs $0.68beat
- Wed, Jul 30$0.66 vs $0.63beat
- Wed, May 7$0.52 vs $0.47beat
Estimates and results for TEVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TEVA officers and directors.
- Bought
- —
- Sold
- $27.5m
0 trades
25 trades
- Zaks Tal Zvisold
- Jover Placidsold
- Hughes Eric Asold
- Shields Matthewsold
- Kalif Eliyahu Sharonsold
- Francis Richard Dsold
- Shields Matthewsold
- Lippman Evansold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.